Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for SDZ.SW and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for SDZ.SW and 80,000+ other tickers.
See exactly how SDZ.SW's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SDZ.SW and 80,000+ other tickers.
Operating globally, Sandoz Group AG specializes in the development, production, and distribution of generic medications and biosimilar products. The company's portfolio includes the creation and sale of finished dosage forms for small molecule pharmaceuticals, often supplied to other entities. Sandoz is also a significant player in the biotechnology sector, providing protein-based products such as biosimilars and offering specialized manufacturing services within this field. Furthermore, it supplies anti-infective products, including active pharmaceutical ingredients (APIs) and intermediates…
All closing requirements satisfied following announcement of a non-binding term-sheet agreement in July and signing of contract in November Agreement includes approximately US$ 350 m in cash for Just - Evotec Biologics manufacturing site in Toulouse and upfront technology license fees to Evotec's continuous manufacturing platform In addition, Evotec eligible for license fees, and development revenues including success-based milestones adding up to more than US$ 300 m over the coming years,replacing existing contractual commitments Transaction covering royalties on a portfolio ofup to ten biosimilars in technical and early development targetingmore than US$ 90 bn of originator net sales Sale immediately earnings accretive, improving Evotec's short, mid and long-term revenue mix, profit margins, and capital efficiency HAMBURG, DE / ACCESS Newswire / December 8, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) today announced the closing of its previously reported sale of the Just - Evotec Biologics Toulouse site plus an indefinite technology license to Evotec's continuous manufacturing platform technology to Sandoz AG (SIX:SDZ / OTCQX:SDZNY), effective 05 December 2025. In total, potential payments may exceed US$ 650 m plus royalties on a portfolio of up to 10 biosimilar molecules, of which six have an originator net sales value of US$ 90 bn.
/PRNewswire/ -- EirGenix Inc. (TWSE: 6589) anunció el 12 de noviembre la firma de un segundo acuerdo global de licencia exclusiva con Sandoz AG
/PRNewswire/ -- EirGenix Inc.(TWSE: 6589) annoncé le 12 novembre la conclusion d'un deuxième accord mondial de licence exclusive avec le leader international
/PRNewswire/ -- EirGenix Inc.(TWSE: 6589) today announced that it has entered into a second global exclusive licensing agreement with international biosimilar